Acne in Skin of Color: Why Standard Acne Protocols Backfire on Fitzpatrick IV-VI

Acne in Fitzpatrick IV–VI should not be treated as if pigment were an afterthought. Standard acne protocols most often backfire not because they stop working, but because they irritate the skin, prolong inflammation, and leave behind more visible post-inflammatory hyperpigmentation (PIH).

For skin of color, the clinical goal is therefore twofold: clear acne early and avoid creating a second problem while treating the first. That means choosing anti-acne therapies with an active but tolerable profile, building in pigment protection, and measuring success by both lesion control and reduction in dyspigmentation.

Why standard acne protocols backfire in Fitzpatrick IV–VI

The central problem in skin of color is not that standard acne medications are ineffective. It is that they can be too irritating, too slow to control inflammation, or too narrowly focused on lesions while ignoring pigment sequelae. In darker phototypes, acne-related inflammation more readily triggers melanin overproduction and deposition, so even modest inflammatory papules can leave a disproportionate visual footprint.

That is why a patient may report that “the acne got better, but the marks got worse.” In Indian practice and broader Fitzpatrick IV–VI care, that pattern usually reflects under-treated inflammation, over-treated skin, or both.

The evidence base is still relatively limited. A 2022 systematic review identified 55 eligible studies, including 28 randomized controlled trials, but also highlighted that much of day-to-day acne guidance in skin of color is still extrapolated from lighter-skin populations. That matters, because tolerability and pigment outcomes are not interchangeable across phototypes.

For a practical framework on acid selection by phototype, see Salicylic, Glycolic, Lactic, or Mandelic: Choosing the Right Peel by Fitzpatrick Type. For acne-oriented peeling options, the protocol pages for S30 - Salicylic Peel and 470 - Azeliac Acnil are useful reference points when building a more pigment-conscious regimen.

The treatment goal in skin of color is inflammation control without iatrogenic PIH

Why PIH is the real endpoint

PIH is a reactive hypermelanosis caused by cutaneous inflammation or injury. Acne is one of its commonest triggers. In skin of color, that means the visible burden of acne is often determined as much by what happens after the lesion settles as by the lesion itself.

The practical implication is simple: if a regimen causes erythema, dryness, burning, or dermatitis, it may be trading acne improvement for pigment persistence. That is not a tolerability issue in the abstract; it is a direct disease-management issue.

What this means in daily prescribing

The most successful protocols in skin of color usually share three features:

• they suppress inflammatory lesions early;
• they avoid unnecessary barrier damage;
• they include daily photoprotection and moisturization.

That approach is consistent with the AAD acne guideline, which strongly supports topical retinoids, benzoyl peroxide, oral antibiotics when indicated, and combination regimens, while conditionally supporting azelaic acid, salicylic acid, clascoterone, and hormonal therapies. The same guideline also notes insufficient evidence for most procedures, including many peel and device-based interventions.

Which acne therapies fit skin of color best

Topical retinoids: foundational, but titrate carefully

Retinoids remain central because they reduce microcomedone formation and help control inflammation. In skin of color, the constraint is usually irritation rather than lack of efficacy. Dryness and peeling can be enough to provoke patient dissatisfaction and, in some cases, contribute to PIH.

The answer is not to avoid retinoids, but to use them intelligently:

• start with alternate-night application;
• introduce one active at a time;
• pair with moisturizer and daily sunscreen;
• escalate only when the skin barrier is stable.

This is why retinoid-first protocols work better when they are barrier-aware rather than potency-led. Emerging data with trifarotene are relevant here, including studies that looked at acne sequelae in skin of color and a phase IV trial spanning Fitzpatrick I–VI with UV protection and appropriate skincare.

Benzoyl peroxide: essential, but not always at full force

Benzoyl peroxide remains strongly recommended because it reduces acne-causing bacteria and supports antibiotic stewardship. In skin of color, however, the issue is often irritant dermatitis, especially when higher strengths are used too often or layered too quickly with other actives.

For darker phototypes, a lower-frequency or combination-based approach is often more realistic than “strongest available, twice daily.” A post-hoc analysis of adapalene/benzoyl peroxide 0.3%/2.5% included Fitzpatrick I–VI, with 89 subjects in FST IV–VI, supporting feasibility across darker skin types.

Azelaic acid: a useful acne-plus-pigment option

Azelaic acid is one of the most clinically sensible choices when PIH is already part of the presentation. The AAD gives it a conditional recommendation and specifically notes its utility for acne and residual dark spots.

For Fitzpatrick IV–VI, that dual action matters. It does not make azelaic acid a universal first-line substitute for all patients, but it does make it especially attractive when inflammatory acne and pigment sequelae are being treated together.

If you are comparing pigment-oriented options, the protocol pages for S15 - Salicylic Peel and Mandelic Acnil are often useful alongside the acne-facing topical strategy.

Oral antibiotics and hormonal therapy: reduce new inflammatory lesions

Oral antibiotics are still appropriate when indicated, but they should be time-limited and paired with benzoyl peroxide. Prolonged antibiotic monotherapy is a poor choice in skin of color because it delays inflammation control without addressing pigment risk and increases resistance pressure.

Hormonal therapy, including combined oral contraceptives and spironolactone, can be valuable in adult or hormonally patterned acne. Their benefit in skin of color is indirect but important: fewer new inflammatory lesions means less opportunity for PIH to develop.

Procedures and peels: when to use them, and when not to

Procedures can be helpful in carefully selected patients, but they are not a shortcut around the fundamentals. In Fitzpatrick IV–VI, procedural irritation can be costly, and the AAD states evidence is insufficient for most acne procedures; it also recommends against adding IPL to adapalene 0.3% gel.

That does not mean peels never belong in acne care. It means they should be adjunctive, not reflexive. When used, they should sit inside a broader plan that already controls inflammation and protects the barrier.

A practical hierarchy for darker phototypes

Clinical situation	Better-fitting approach
Mild acne with prominent PIH	Azelaic acid, gentle retinoid initiation, sunscreen
Comedonal or mixed acne with sensitive skin	Low-irritancy retinoid + BPO as tolerated
Moderate inflammatory acne	Combination topical therapy; add oral therapy if needed
Acne with recurrent PIH after irritation	Reassess strength, frequency, cleanser, moisturizer, and photoprotection
Stable patient seeking adjunctive in-clinic treatment	Consider highly protocolized peels with careful follow-up

For operators who use peels in acne-prone skin of color, the key is not to “push through” irritation. If the skin is already inflamed or barrier-compromised, escalation increases the risk of visible dyspigmentation. A more conservative approach is usually safer.

Related reading: Managing Post-Peel PIH in Indian Skin: A Clinical Checklist and Glycolic 70% Acid Peel: Clinical Protocol, Indications & Safety.

How to build a Fitzpatrick IV–VI acne protocol that does not create more PIH

The most reliable protocol is usually the simplest one that the patient can actually sustain.

Core principles

1. Treat inflammation early. Delayed control means more lesions and more PIH.
2. Avoid barrier overload. Too many actives, too fast, creates irritation that can persist as pigment.
3. Use combination therapy when inflammation is moderate. This is often more effective than prolonged monotherapy.
4. Pair antibiotics with benzoyl peroxide. This supports resistance stewardship.
5. Make sunscreen part of acne treatment. UV exposure can prolong pigment visibility.

A useful way to think about this is that acne care in skin of color is pigment-prevention care. That is why cleanser choice, moisturizer support, and sunscreen are not cosmetic add-ons; they are treatment infrastructure.

For clinics that use in-house peel programs, product selection should reflect this same logic. S30 - Salicylic Peel is more relevant for oily, comedonal, acne-prone skin, while 470 - Azeliac Acnil aligns better when dyspigmentation is prominent.

Bottom line

In Fitzpatrick IV–VI, the correct acne protocol is not the most aggressive one. It is the one that clears inflammation quickly enough to prevent PIH, while avoiding the irritancy that prolongs dyspigmentation.

That usually means a combination of topical retinoids, benzoyl peroxide, azelaic acid when pigment is prominent, time-limited oral therapy when needed, and strong attention to barrier support and UV protection. Procedures and peels may have a role, but only as carefully selected adjuncts in a protocol already designed for skin of color.

For clinicians building that workflow, the most useful mindset is simple: treat acne, but do not ignore the pigment it leaves behind.